One To Watch

Ferring Pharmaceuticals

A privately-owned Swiss biopharmaceutical group with deep expertise in reproductive medicine, urology, and gastroenterology, committed to helping people build families and live better lives through innovative medicines and gene therapies.

Company Overview

Ferring Pharmaceuticals is a privately-owned, research-driven biopharmaceutical group headquartered in Saint-Prex, Switzerland. The company develops, manufactures, and markets innovative medicines across reproductive medicine and maternal health, urology and uro-oncology, and gastroenterology. Ferring employs more than 7,500 people in over 50 countries and markets its products in more than 100 countries. In 2025, total revenues exceeded €2.5 billion, representing a 10% increase from 2024, driven primarily by the flagship fertility product Menopur. Ferring is at the forefront of gene therapy innovation in uro-oncology, with its gene therapy Adstiladrin approved by the US FDA for BCG-unresponsive non-muscle invasive bladder cancer.

Headquarters and Global Presence

Ferring's global headquarters are located in Saint-Prex, on the shores of Lake Geneva in Switzerland. The company operates through its own subsidiaries in more than 50 countries, with key operational hubs across North America, Europe, and Asia. R&D centres are maintained in ten countries including Denmark, Switzerland, the United States, Israel, Japan, China, and India. Primary pharmaceutical development hubs are situated in Copenhagen, Denmark, and San Diego, California. In the United States, manufacturing operations are based in Parsippany, New Jersey, where the company received FDA approval for its Adstiladrin gene therapy manufacturing facility.

Founding and History

Ferring Pharmaceuticals was founded in 1950 by Dr. Frederik Paulsen Sr. and Dr. Eva Paulsen in Malmö, Sweden, initially as Nordiska Hormon Laboratoriet, renamed Ferring in 1954. The name was inspired by the Feringers, the close-knit community of Föhr island, reflecting the company's founding values. From its earliest years, Ferring established scientific distinction through the industrial-scale synthesis of peptide hormones, producing oxytocin and vasopressin as breakthrough achievements in the 1960s. These discoveries shaped the company's long-term orientation towards reproductive endocrinology and peptide pharmacology. Over subsequent decades, Ferring expanded geographically and therapeutically, evolving from a Scandinavian peptide hormone specialist into a global biopharmaceutical group. The company has remained privately held throughout its history.

Therapy Areas and Focus

Ferring's three primary therapeutic areas are reproductive medicine and maternal health, urology and uro-oncology, and gastroenterology and immunology. In reproductive medicine, the company holds a leading position with gonadotrophins and ovulation induction agents supporting assisted reproduction. In maternal health, Ferring develops and promotes products for preventing and managing postpartum haemorrhage, working with international NGOs to improve maternal outcomes in low- and middle-income countries. In urology, Ferring has transitioned into gene therapy with Adstiladrin for bladder cancer. Gastroenterology represents a complementary focus, with Ferring exploring microbiome-based approaches alongside conventional pharmacological interventions.

Technology Platforms and Modalities

Ferring's historical scientific foundation lies in peptide hormone chemistry, underpinning its reproductive medicine and maternal health products including gonadotrophins, GnRH analogues, and oxytocin-based agents. In uro-oncology, the company has invested significantly in gene therapy, with Adstiladrin (nadofaragene firadenovec-vncg) representing an adenoviral vector-based intravesical gene therapy delivering interferon-alpha 2b to the bladder. In gastroenterology, Ferring has established a strategic partnership with PharmaBiome to explore microbiome-modulating therapeutics, reflecting its interest in biological platforms beyond traditional small molecules. The company also pursues in-licensing and external innovation through a dedicated External Innovation Sourcing Group targeting its core therapeutic areas.

Key Pipeline and Programs

Adstiladrin (nadofaragene firadenovec-vncg) is Ferring's most advanced innovative product, an FDA-approved intravesical gene therapy for BCG-unresponsive non-muscle invasive bladder cancer, which is also being investigated in combination with the investigational photodynamic agent Ruvidar (TLD-1433). Follitropin delta is a recombinant follicle-stimulating hormone in development for reproductive medicine, currently in Phase 2 trials. Ferring maintains a pipeline of 24 drugs in development spanning its core areas, including gastroenterological assets arising from the collaboration with Conaris for a recombinant molecule in gastroenterology. The company has 14 major strategic collaborations advancing external innovation across its therapeutic areas.

Key Personnel

Jean-Frédéric Paulsen was appointed Chief Executive Officer of Ferring Pharmaceuticals on 1 February 2026, simultaneously continuing as Chairman of the Board, a dual role designed to support greater operational agility during the company's global transformation programme. He is a member of the founding Paulsen family, which has guided the company since its establishment in 1950. Klaus Dugi serves as Executive Vice President and Chief Medical Officer, providing oversight of clinical and medical affairs. André Overmeyer joined as head of global plant operations from March 2026, having previously served as Senior Vice President at Merck Life Science. The Board was also strengthened by the addition of Viviane Monges, a former CFO of Wyeth Pharmaceuticals/Pfizer and Novartis.

Strategic Partnerships

Ferring's most significant commercial partnership in uro-oncology is its collaboration with FGF Therapeutics (FerGene), a joint venture established to commercialise Adstiladrin in the United States. In gastroenterology, Ferring signed a microbiome R&D partnership with PharmaBiome and completed a licence agreement with Conaris for a novel recombinant molecule. In maternal health, Ferring has an ongoing strategic alliance with the NGO Maternity Foundation aimed at preventing postpartum haemorrhage in low-and middle-income countries. The company has launched an External Innovation Sourcing Group to increase collaboration with biotechs and academic institutions across reproductive medicine, urology, and gastroenterology. Ferring maintains 14 major strategic collaborations overall, reflecting a deliberate commitment to externally sourced innovation alongside its proprietary R&D.

FAQ Section

Ferring's central strategic issue is balancing investment in gene therapy and pipeline innovation, particularly the commercialisation of Adstiladrin in bladder cancer, alongside ongoing cost optimisation following the October 2025 operational restructuring that targeted a reduction of up to 500 roles globally.

BCG-unresponsive non-muscle invasive bladder cancer represents a high-unmet-need population where standard treatments have failed, often leaving patients facing radical cystectomy; Adstiladrin offers a bladder-sparing gene therapy option that can preserve quality of life in this difficult-to-treat group.

Ferring differentiates itself through its status as a privately-held, family-founded company with the flexibility to take long-term scientific positions, combined with its unique combination of peptide hormone heritage in reproductive medicine and frontier gene therapy capabilities in uro-oncology within a single focused organisation.

Adstiladrin is the first and only intravesical gene therapy approved for BCG-unresponsive non-muscle invasive bladder cancer, delivering interferon-alpha 2b directly to bladder tissue via an adenoviral vector and achieving complete response rates in a population with no other bladder-preserving options.

Ferring's pipeline is defined by reproductive medicine and maternal health, uro-oncology gene therapy, and gastroenterology and immunology, with 24 drugs in development spanning recombinant hormones, gene therapy combinations, microbiome-modulating agents, and novel small molecules in-licensed from external partners.

Ferring is a mature, revenue-generating commercial company with annual revenues exceeding €2.5 billion from its fertility and urology portfolio, while simultaneously investing in next-generation gene therapy and microbiome platforms to drive future growth and pipeline diversification.

Key watchpoints include the commercial uptake trajectory of Adstiladrin for bladder cancer, the outcome of the global operational restructuring announced in October 2025, progress of the Adstiladrin combination study with Ruvidar, and the company's ability to sustain fertility market leadership against growing biosimilar and generic competition.

Want to Update your Company's Profile?